Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. (FNCH) priced its initial public offering on Mar 22, 2021 at $17.00 per share, within its $15.00–$17.00 range, raising $127.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $801.5M. BofA Securities was lead-left underwriter, joined by Jefferies and Evercore ISI. Cooley advised the company and Goodwin Procter advised the underwriters.

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company developing orally administered biological drugs through its Human-First Discovery platform. The drugs deliver missing microbes to correct dysbiosis, and its lead candidate, CP101, delivers a complete microbiome for recurrent C. difficile infection.

Status

IPO

Ticker

FNCH

Exchange

Nasdaq Global Select

Priced

Mar 22, 2021

IPO price

$17.00

Price range

$15.00–$17.00

Raised

$127.5M

Market cap at IPO price

$801.5M

First filed

Feb 26, 2021

Underwriters

BofA Securities, Jefferies and Evercore ISI

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.